U.S. Drug Tariffs Seen as Sparing Taiwan Prices, Supply

Why It Matters

Taiwan’s pharmaceutical sector avoids price shocks and supply risks, preserving its competitive edge in the U.S. generic market and reinforcing bilateral trade stability amid shifting U.S. trade policy.

Key Takeaways

• Taiwan exports 86.5% generics to U.S.
• US tariffs target patented drugs, not generics.
• ART guarantees generic exemption for one year.
• Patented drug exports from Taiwan valued at NT$1.32 bn.
• TFDA will streamline U.S. import reviews.

Pulse Analysis

The Trump administration’s recent drug‑tariff order reflects a broader push to repatriate pharmaceutical manufacturing and leverage pricing pressure on patented medicines. By levying up to a 100% duty on foreign‑made branded drugs, Washington aims to incentivize domestic production and negotiate more favorable trade terms. While major economies have secured reduced rates through existing agreements, the policy’s ripple effects are being closely watched by export‑dependent markets that rely on the U.S. as a key destination for their pharmaceutical output.

Taiwan’s drug export profile is heavily weighted toward generics and active pharmaceutical ingredients (APIs), which are largely insulated from the new tariffs. According to the Food and Drug Administration, generics account for 86.5% of Taiwan’s pharmaceutical shipments to the United States, amounting to NT$8.47 billion in 2024. The one‑year generic exemption embedded in the pending Agreement on Reciprocal Trade (ART) and reinforced by a bilateral investment memorandum ensures that these products remain duty‑free, preserving Taiwan’s price competitiveness and supply chain continuity. Moreover, the Supreme Court’s recent ruling deeming the reciprocal tariff framework unconstitutional adds a legal layer that may further protect Taiwan’s trade interests.

For Taiwan’s health sector, the immediate outlook remains stable, but the episode underscores the importance of diversified market access and proactive diplomatic engagement. Continued dialogue with Washington will be essential to extend generic exemptions beyond the provisional period and to address any future adjustments to the tariff schedule. Regionally, other Asian exporters observing Taiwan’s experience may seek similar safeguards, potentially reshaping the global landscape of pharmaceutical trade negotiations and prompting a reassessment of supply‑chain resilience strategies across the industry.